No Data
No Data
Zhejiang Jianfeng Group's announcement of a decrease in performance for the first half of 2024.
Zhejiang Jianfeng Group (600668.SH) is expected to have a net income decrease of 49.83% to 65.96% in the first half of the year.
On July 9th, Gelunhui reported that Zhejiang Jianfeng Group (600668.SH) announced that based on preliminary calculations by the finance department, it is expected to achieve a net income of 38 million to 56 million yuan attributable to shareholders of the listed company in the first half of 2024. Compared with the same period last year, it will decrease by 55.6218 million to 73.6218 million yuan, a year-on-year decrease of 49.83% to 65.96%. It is expected to achieve a net income after deducting non-recurring gains and losses attributable to shareholders of the listed company of 30 million to 45 million yuan in the first half of 2024, a decrease of 56.6971 million yuan compared to the same period last year.
Zhejiang Jianfeng Group (600668.SH): Oseltamivir phosphate capsules has obtained the pharmaceutical registration certificate.
On July 5th, Gelonhui reported that Zhejiang Jianfeng Pharmaceutical Co., Ltd. (referred to as Jianfeng Pharmaceutical), a wholly-owned subsidiary of Zhejiang Jianfeng Group (600668.SH), received the approval and issuance of the registration certificate for oseltamivir phosphate capsules from the National Medical Products Administration (certificate number: 2024S01534). This means that Jianfeng Pharmaceutical is qualified to produce and sell this pharmaceutical, which will further enrich its product variety and help enhance the company's competitiveness in the pharmaceutical business.
Zhejiang Jianfeng Group Receives Drug Registration for Sodium Hyaluronate Eye Drops
Zhejiang Jianfeng Group (SHA:600668) received the drug registration certificate of sodium hyaluronate eye drops. The registration is expected to further enrich the company's product line and help enha
Zhejiang Jianfeng Group (600668.SH): Received the pharmaceutical registration certificate for sodium boric acid eye drops.
Jianfeng Group (600668.SH) announced that its wholly-owned subsidiary Zhejiang Jianfeng Pharmaceutical Co., Ltd. (referred to as "Jianfeng Pharmaceutical") and its controlling subsidiary Zhejiang Erying Pharmaceutical Co., Ltd. (referred to as "Erying Company") has received the drug registration certificate for sodium hyaluronate eye drops issued by the National Medical Products Administration.
China Approves Jianfeng's Marketing Application for Antibiotic Raw Material
China approved Zhejiang Jianfeng Group (SHA:600668) subsidiary Zhejiang Jianfeng Pharmaceutical's marketing application for its cefmenoxime hydrochloride raw material, according to a Tuesday filing wi
No Data